Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1589

Treatment of Seizures and Prevention of Long-Term Epilepsy

Inventors: Frances Jensen, Sanjay Rakhade, Chengwen Zhou

Invention Types: Therapeutics

Research Areas: Neonatology/Pediatric, Neurology/Neuroscience

Keywords: Animal Model (rat), Disease Model, Method of Use, Small Molecule/Drug

For More Information Contact:  Caron, Connie

 

Invention Description:

Investigators at Children's Hospital Boston have discovered a cascade of molecular events that are triggered by seizures, thereby uncovering targets for therapeutics that could be targeted drugs. Results show that use of AMPA receptor antagonists can block the processes of epileptogenesis.

The Jensen laboratory's sophisticated rat model for inducing and studying the downstream effects of seizures and the epileptogenesis processes can be used to identify new targets and pathways that could be promising in the treatment of epilepsy and also autism, which, for many patients, is associated with seizures.

Applications:

Epilepsy|Seizures|Autism

Competitive Advantages:

The targets and therapeutics described in this invention represent novel pathways in the treatment and prevention of long-term epilepsy. The described invention represents a new treatment modality for epilepsy, with the possibility of developing a first-in-class therapeutic compound.

Business Opportunity:

There are many drugs on the market that address epilepsy, though not all work equally well for all patients. The discovery of new pathways associated with the development of long-term epilepsy and autism opens up the potential for developing new therapeutics and to use these to address seizure disorders earlier and also as adjuncts to the existing therapies.

Exclusive License|Sponsored research|Collaboration

Key Publications: Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures.
|Rakhade SN, Zhou C, Aujla PK, Fishman R, Sucher NJ, Jensen FE.
|J Neurosci. 2008 Aug 6;28(32):7979-90.

IPStatus: Pat. Pend.